Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Abubaker, Khalid ^a,b   Latifi, Ardian ^a,b   Luwor, Rod ^b   Nazaretian, Simon ^a   Zhu, Hongjian ^b   Quinn, Michael A ^a,b   Thompson, Erik W ^b,c   Findlay, Jock K ^a,b,d   Ahmed, Nuzhat ^a,b,d  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Ascites; Cancer stem cell; Chemoresistance; Metastasis; Ovarian carcinoma; Recurrence

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; KI 67 ANTIGEN; OCTAMER TRANSCRIPTION FACTOR 4; PACLITAXEL; STEM CELL FACTOR RECEPTOR; UVOMORULIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER STEM CELL; CELL INFILTRATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OVARY CANCER; PERITONEAL CAVITY; PROTEIN EXPRESSION; TUMOR VOLUME;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL POLARITY; CISPLATIN; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOPHENOTYPING; MICE; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PHENOTYPE; RNA, MESSENGER; SPHEROIDS, CELLULAR; TUBULIN; TUMOR BURDEN; TUMOR CELLS, CULTURED;

MUS;

EID: 84875320058     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-24     Document Type: Article

References (56)

1. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010, 177:1053-1064. 10.2353/ajpath.2010.100105, 2928939, 20651229.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6. 10.1056/NEJM199601043340101, 7494563.
3. Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy. Cancer Res 1999, 59:2425-2432.
4. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994, 69:299-306. 10.1038/bjc.1994.55, 1968703, 7905279.
5. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993, 55:678-684. 10.1002/ijc.2910550428, 8406999.
6. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56:556-562.
7. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014. 10.1056/NEJM199504133321507, 7885406.
8. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1995, 1:506-526. 2229961, 8529117.
9. Gabra H, Back to the future Targeting molecular changes for platinum resistance reversal. Gynecol Oncol 2010, 118:210-211. 10.1016/j.ygyno.2010.06.028, 20691332, Back to the future.
10. Hollier BG, Evans K, Mani SA. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 2009, 14:29-43. 10.1007/s10911-009-9110-3, 19242781.
11. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 2011, 112:2850-2864. 10.1002/jcb.23199, 21618587.
12. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010, 10:268-278. 10.2174/156800910791190175, 20370691.
13. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One 2012, 7:e46858. 10.1371/journal.pone.0046858, 3466197, 23056490.
14. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2012, 18:869-881. 10.1158/1078-0432.CCR-11-2188, 3271164, 22142828.
15. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005, 65:3025-3029.
16. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006, 103:11154-11159. 10.1073/pnas.0603672103, 1544057, 16849428.
17. Szotek PP, Chang HL, Brennand K, Fujino A, Pieretti-Vanmarcke R, Lo Celso C, Dombkowski D, Preffer F, Cohen KS, Teixeira J, Donahoe PK. Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proc Natl Acad Sci USA 2008, 105:12469-12473. 10.1073/pnas.0805012105, 2527935, 18711140.
18. Aguilar-Gallardo C, Rutledge EC, Martinez-Arroyo AM, Hidalgo JJ, Domingo S, Simon C, Overcoming Challenges of Ovarian Cancer Stem Cells Novel Therapeutic Approaches. Stem Cell Rev 2012, 8:994-1010. 10.1007/s12015-011-9344-5, 22278130, Overcoming Challenges of Ovarian Cancer Stem Cells.
19. Ahmed N, Abubaker K, Findlay J, Quinn M. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. J Cell Biochem 2013, 114:21. 10.1002/jcb.24317, 22887554.
20. Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci 2011, 16:368-392. 10.2741/3693, 21196176.
21. Buick RN, Pullano R, Trent JM. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 1985, 45:3668-3676.
22. Shield K, Riley C, Quinn MA, Rice GE, Ackland ML, Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog 2007, 6:11. 10.1186/1477-3163-6-11, 1929068, 17567918.
23. Ahmed N, Pansino F, Clyde R, Murthi P, Quinn MA, Rice GE, Agrez MV, Mok S, Baker MS. Overexpression of alpha(v)beta6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade. Carcinogenesis 2002, 23:237-244. 10.1093/carcin/23.2.237, 11872628.
24. van der Poorten D, Shahidi M, Tay E, Sesha J, Tran K, McLeod D, Milliken JS, Ho V, Hebbard LW, Douglas MW, George J. Hepatitis C virus induces the cannabinoid receptor 1. PLoS One 2010, 5:e12841. 10.1371/journal.pone.0012841, 2941472, 20862263.
25. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003, 63:1311-1316.
26. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997, 100:1282-1293. 10.1172/JCI119642, 508306, 9276747.
27. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010, 102:1276-1283. 10.1038/sj.bjc.6605626, 2856005, 20354527.
28. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One 2012, 7:e29079. 10.1371/journal.pone.0029079, 3260150, 22272227.
29. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994, 94:703-708. 10.1172/JCI117388, 296149, 8040325.
30. De Donato M, Mariani M, Petrella L, Martinelli E, Zannoni GF, Vellone V, Ferrandina G, Shahabi S, Scambia G, Ferlini C. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012, 227:1034-1041. 10.1002/jcp.22813, 21520077.
31. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-991. 10.1056/NEJMoa060570, 16957145.
32. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996, 56:2584-2589.
33. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 2000, 275:17358-17363. 10.1074/jbc.M000966200, 10749863.
34. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998, 77:562-566. 10.1038/bjc.1998.91, 2149944, 9484812.
35. Wintzell M, Lofstedt L, Johansson J, Pedersen AB, Fuxe J, Shoshan M. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol Ther 2012, 13:1454-1462. 10.4161/cbt.22007, 22954696.
36. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010, 24:837-852. 10.1101/gad.1897010, 2854397, 20395368.
37. Hosonuma S, Kobayashi Y, Kojo S, Wada H, Seino K, Kiguchi K, Ishizuka B. Clinical significance of side population in ovarian cancer cells. Hum Cell 2011, 24:9-12. 10.1007/s13577-010-0002-z, 3051070, 21547690.
38. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8:158-166. 10.4161/cc.8.1.7533, 3041590, 19158483.
39. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68:4311-4320. 10.1158/0008-5472.CAN-08-0364, 2553722, 18519691.
40. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2672-2680. 10.1038/onc.2010.35, 20190812.
41. Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res 2011, 71:634-639. 10.1158/0008-5472.CAN-10-3220, 21266356.
42. Harless WW. Cancer treatments transform residual cancer cell phenotype. Cancer Cell Int 2011, 11:1. 10.1186/1475-2867-11-1, 3022788, 21214935.
43. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer 2008, 123:2031-2040. 10.1002/ijc.23732, 2574811, 18697197.
44. Park SY, Kwon HJ, Choi Y, Lee HE, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes. Mod Pathol 2012, 25:185-196.
45. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 2009, 100:134-144. 10.1038/sj.bjc.6604794, 2634691, 19088723.
46. Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 2007, 213:581-588. 10.1002/jcp.21240, 17708542.
47. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev 2012, 31:673-687. 10.1007/s10555-012-9370-z, 22733306.
48. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ, E-cadherin's dark side Possible role in tumor progression. Biochim Biophys Acta 1826, 2012:23-31. E-cadherin's dark side.
49. Gunasinghe NP, Wells A, Thompson EW, Hugo HJ. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev 2012, 31:469-478. 10.1007/s10555-012-9377-5, 22729277.
50. Jiang H, Lin X, Liu Y, Gong W, Ma X, Yu Y, Xie Y, Sun X, Feng Y, Janzen V, Chen T. Transformation of Epithelial Ovarian Cancer Stem-like Cells into Mesenchymal Lineage via Epithelial-Mesenchymal Transition Results in Cellular Heterogeneity which Enables Tumor Engraftment. Mol Med 2012, 18:1197-208. 3510297, 22801793.
51. Chao Y, Wu Q, Shepard C, Wells A. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis 2012, 29:39-50. 10.1007/s10585-011-9427-3, 21964676.
52. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ. Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS One 2010, 5:e13665. 10.1371/journal.pone.0013665, 2965143, 21060868.
53. Celia-Terrassa T, Meca-Cortes O, Mateo F, de Paz AM, Rubio N, Arnal-Estape A, Ell BJ, Bermudo R, Diaz A, Guerra-Rebollo M. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest 2012, 122:1849-1868. 10.1172/JCI59218, 3366719, 22505459.
54. Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012, 30:292-303. 10.1002/stem.791, 22102611.
55. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913. 10.1038/nm.2000, 19648928.
56. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, Gilmore H, Tung N, Naber SP, Schnitt S. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 2011, 8:149-163. 10.1016/j.stem.2010.12.007, 3050563, 21295272.